BI breathes easy after Spiriva trumps LABAs in old school German HTA
This article was originally published in Scrip
Boehringer Ingelheim's top selling drug, Spiriva (tiotropium) offers additional benefit compared to placebo and long-acting beta-2 agonists (LABAs), says a report from IQWiG, Germany's Institute of Quality and Efficiency in Healthcare. The findings mark a more positive endorsement of the drug than the institute's previous report published in November, which concluded that Spiriva offered additional benefit in comparison only to one LABA, salmeterol.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.